Cargando…
NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation
Glioblastoma multiforme (GBM) is a highly heterogeneous disease with a mesenchymal subtype tending to exhibit more aggressive and multitherapy-resistant features. Glioblastoma stem-cells derived from mesenchymal cells are reliant on iron supply, accumulated with high reactive oxygen species (ROS), a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178261/ https://www.ncbi.nlm.nih.gov/pubmed/37175412 http://dx.doi.org/10.3390/ijms24097706 |
_version_ | 1785040819671007232 |
---|---|
author | Su, I-Chang Su, Yu-Kai Setiawan, Syahru Agung Yadav, Vijesh Kumar Fong, Iat-Hang Yeh, Chi-Tai Lin, Chien-Min Liu, Heng-Wei |
author_facet | Su, I-Chang Su, Yu-Kai Setiawan, Syahru Agung Yadav, Vijesh Kumar Fong, Iat-Hang Yeh, Chi-Tai Lin, Chien-Min Liu, Heng-Wei |
author_sort | Su, I-Chang |
collection | PubMed |
description | Glioblastoma multiforme (GBM) is a highly heterogeneous disease with a mesenchymal subtype tending to exhibit more aggressive and multitherapy-resistant features. Glioblastoma stem-cells derived from mesenchymal cells are reliant on iron supply, accumulated with high reactive oxygen species (ROS), and susceptible to ferroptosis. Temozolomide (TMZ) treatment is the mainstay drug for GBM despite the rapid development of resistance in mesenchymal GBM. The main interconnection between mesenchymal features, TMZ resistance, and ferroptosis are poorly understood. Herein, we demonstrated that a subunit of NADPH oxidase, CYBB, orchestrated mesenchymal shift and promoted TMZ resistance by modulating the anti-ferroptosis circuitry Nrf2/SOD2 axis. Public transcriptomic data re-analysis found that CYBB and SOD2 were highly upregulated in the mesenchymal subtype of GBM. Accordingly, our GBM cohort confirmed a high expression of CYBB in the GBM tumor and was associated with mesenchymal features and poor clinical outcome. An in vitro study demonstrated that TMZ-resistant GBM cells displayed mesenchymal and stemness features while remaining resilient to erastin-mediated ferroptosis by activating the CYBB/Nrf2/SOD2 axis. The CYBB maintained a high ROS state to sustain the mesenchymal phenotype, TMZ resistance, and reduced erastin sensitivity. Mechanistically, CYBB interacted with Nrf2 and consequently regulated SOD2 transcription. Compensatory antioxidant SOD2 essentially protected against the deleterious effect of high ROS while attenuating ferroptosis in TMZ-resistant cells. An animal study highlighted the protective role of SOD2 to mitigate erastin-triggered ferroptosis and tolerate oxidative stress burden in mice harboring TMZ-resistant GBM cell xenografts. Therefore, CYBB captured ferroptosis resilience in mesenchymal GBM. The downstream compensatory activity of CYBB via the Nrf2/SOD2 axis is exploitable through erastin-induced ferroptosis to overcome TMZ resistance. |
format | Online Article Text |
id | pubmed-10178261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101782612023-05-13 NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation Su, I-Chang Su, Yu-Kai Setiawan, Syahru Agung Yadav, Vijesh Kumar Fong, Iat-Hang Yeh, Chi-Tai Lin, Chien-Min Liu, Heng-Wei Int J Mol Sci Article Glioblastoma multiforme (GBM) is a highly heterogeneous disease with a mesenchymal subtype tending to exhibit more aggressive and multitherapy-resistant features. Glioblastoma stem-cells derived from mesenchymal cells are reliant on iron supply, accumulated with high reactive oxygen species (ROS), and susceptible to ferroptosis. Temozolomide (TMZ) treatment is the mainstay drug for GBM despite the rapid development of resistance in mesenchymal GBM. The main interconnection between mesenchymal features, TMZ resistance, and ferroptosis are poorly understood. Herein, we demonstrated that a subunit of NADPH oxidase, CYBB, orchestrated mesenchymal shift and promoted TMZ resistance by modulating the anti-ferroptosis circuitry Nrf2/SOD2 axis. Public transcriptomic data re-analysis found that CYBB and SOD2 were highly upregulated in the mesenchymal subtype of GBM. Accordingly, our GBM cohort confirmed a high expression of CYBB in the GBM tumor and was associated with mesenchymal features and poor clinical outcome. An in vitro study demonstrated that TMZ-resistant GBM cells displayed mesenchymal and stemness features while remaining resilient to erastin-mediated ferroptosis by activating the CYBB/Nrf2/SOD2 axis. The CYBB maintained a high ROS state to sustain the mesenchymal phenotype, TMZ resistance, and reduced erastin sensitivity. Mechanistically, CYBB interacted with Nrf2 and consequently regulated SOD2 transcription. Compensatory antioxidant SOD2 essentially protected against the deleterious effect of high ROS while attenuating ferroptosis in TMZ-resistant cells. An animal study highlighted the protective role of SOD2 to mitigate erastin-triggered ferroptosis and tolerate oxidative stress burden in mice harboring TMZ-resistant GBM cell xenografts. Therefore, CYBB captured ferroptosis resilience in mesenchymal GBM. The downstream compensatory activity of CYBB via the Nrf2/SOD2 axis is exploitable through erastin-induced ferroptosis to overcome TMZ resistance. MDPI 2023-04-22 /pmc/articles/PMC10178261/ /pubmed/37175412 http://dx.doi.org/10.3390/ijms24097706 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Su, I-Chang Su, Yu-Kai Setiawan, Syahru Agung Yadav, Vijesh Kumar Fong, Iat-Hang Yeh, Chi-Tai Lin, Chien-Min Liu, Heng-Wei NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation |
title | NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation |
title_full | NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation |
title_fullStr | NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation |
title_full_unstemmed | NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation |
title_short | NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation |
title_sort | nadph oxidase subunit cybb confers chemotherapy and ferroptosis resistance in mesenchymal glioblastoma via nrf2/sod2 modulation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178261/ https://www.ncbi.nlm.nih.gov/pubmed/37175412 http://dx.doi.org/10.3390/ijms24097706 |
work_keys_str_mv | AT suichang nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation AT suyukai nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation AT setiawansyahruagung nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation AT yadavvijeshkumar nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation AT fongiathang nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation AT yehchitai nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation AT linchienmin nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation AT liuhengwei nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation |